Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: Evidence for premature aging of the myeloid compartment

被引:8
|
作者
Lobetti-Bodoni, Chiara [1 ]
Ferrero, Dario [1 ]
Genuardi, Elisa [1 ]
Passera, Roberto
Bernocco, Elisa [1 ]
Sia, Daniela [2 ]
Grignani, Giovanni [3 ]
Crisa, Elena [1 ]
Monitillo, Luigia [1 ]
Rocci, Alberto [1 ]
Drandi, Daniela [1 ]
Giai, Valentina [1 ]
Zanni, Manuela [1 ]
Boi, Michela [1 ]
Isaia, Gianluca [4 ]
Barbero, Daniela [1 ]
Lunghi, Monia [5 ]
Abruzzese, Elisabetta [6 ]
Radaelli, Franca [7 ]
Pini, Massimo [8 ]
Pregno, Patrizia [9 ]
Carlo-Stella, Carmelo [2 ]
Gaidano, Gianluca [5 ]
Boccadoro, Mario [1 ]
Ladetto, Marco [1 ]
机构
[1] Univ Turin, Div Hematol, AOU San Giovanni Battista, Turin, Italy
[2] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[3] Inst Canc Res & Treatment IRCC, Med Oncol Unit, Candiolo, Italy
[4] Univ Turin, Dept Med & Surg, Geriatr Sect, Turin, Italy
[5] Amedeo Avogadro Univ Eastern Piedmont, Dept Clin & Expt Med, Div Hematol, Novara, Italy
[6] Tor Vergata Univ Hosp, Dept Hematol, Rome, Italy
[7] Fdn IRCCS Policlin, Milan, Italy
[8] AO SS Antonio & Biagio, Div Hematol, Alessandria, Italy
[9] AOU San Giovanni Battista, Div Hematol 2, Turin, Italy
关键词
Telomere shortening; Cytogenetic abnormalities; Bone marrow failure; Tyrosine kinase inhibitors; Hematopoiesis; IMATINIB MESYLATE THERAPY; CLONAL CYTOGENETIC ABNORMALITIES; CHRONIC MYELOGENOUS LEUKEMIA; HIGH-DOSE CHEMOTHERAPY; CHROMOSOMAL-ABNORMALITIES; POLYCLONAL HEMATOPOIESIS; CELLULAR SENESCENCE; CHRONIC-PHASE; DNA-DAMAGE; STEM-CELLS;
D O I
10.1016/j.mad.2012.05.007
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Telomere shortening, a well-known marker of aging and cellular stress, occurs under several conditions in the hematopoietic compartment, including aplastic anemia and following iatrogenic noxae. We decided to verify whether pathological telomere erosion also arises in restored Philadelphia-negative (Ph-negative) hematopoiesis following successful treatment of chronic myeloid leukemia (CML). Eighty-one CML patients in complete cytogenetic remission were compared to 76 age-matched healthy subjects. Myeloid cells of CML patients had shorter telomeres than controls (6521 bp vs 7233 bp, p < 0.001). This difference was specific for the myeloid compartment, since it was not observed in lymphoid cells (6774 bp vs 6909 bp, p = 0.620). Acquired Ph-negative cytogenetic abnormalities (p = 0.010), lack of complete molecular remission (p = 0.016) and age (p = 0.013) were independent predictors of telomere shortening. Telomere dynamics were assessed over a median follow-up period of 22 months. We. documented accelerated non-physiological ongoing telomere shortening in 17/59 CML patients (28%). Patients experiencing grade 2-4 hematological toxicity, during CML remission possessed significantly shorter telomeres compared to those lacking toxicity (p = 0.005 for any toxicity, p = 0.007 for anemia). CML patients suffer from significant and often ongoing telomere stress resulting in premature and selective aging of the myeloid compartment which might have long-term consequences on function and integrity of Ph-negative hematopoiesis. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:479 / 488
页数:10
相关论文
共 50 条
  • [1] Philadelphia-negative clonal hematopoiesis is a significant feature of dasatinib therapy for chronic myeloid leukemia
    De Melo, Valeria A. S.
    Milojkovic, Dragana
    Khorashad, Jamshid S.
    Marin, David
    Goldman, John M.
    Apperley, Jane F.
    Reid, Alistair G.
    BLOOD, 2007, 110 (08) : 3086 - 3087
  • [2] Philadelphia-negative chromosomal evolution during treatment for chronic myeloid leukemia
    Hsiao, H. -H.
    Liu, Y. -C.
    Lee, C. -P.
    Chang, C. -S.
    Lin, S. -F.
    GENETICS AND MOLECULAR RESEARCH, 2012, 11 (01) : 317 - 321
  • [3] Philadelphia-negative clonal hematopoiesis following imatinib therapy in patients with chronic myeloid leukemia (CML).
    Lin, YL
    Bruyere, H
    Horsman, DE
    Barnett, MJ
    Hogge, DE
    Nevill, TJ
    Nantel, SH
    Sutherland, HJ
    Toze, CL
    Shepherd, JD
    Lavoie, JC
    Song, KW
    Smith, CA
    Forrest, DL
    BLOOD, 2004, 104 (11) : 258B - 258B
  • [4] Translocation of BCR to chromosome 9 in a Philadelphia-negative chronic myeloid leukemia
    Brunel, V
    Sainty, D
    Costello, R
    Mozziconacci, MJ
    Simonetti, A
    Arnoulet, C
    Coignet, L
    Bouabdallah, R
    Gastaut, JA
    Gabert, J
    LafagePochitaloff, M
    CANCER GENETICS AND CYTOGENETICS, 1995, 85 (01) : 82 - 84
  • [5] Philadelphia-negative acute myeloid leukemia with new chromosomal abnormalities developing after first-line imatinib treatment for chronic phase chronic myeloid leukemia
    Fava, Carmen
    Cortes, Jorge
    AMERICAN JOURNAL OF HEMATOLOGY, 2008, 83 (09) : 755 - 755
  • [6] Clinical and biological aspects of Philadelphia-negative/BCR-negative chronic myeloid leukemia
    Costello, R
    Sainty, D
    LafagePochitaloff, M
    Gabert, J
    LEUKEMIA & LYMPHOMA, 1997, 25 (3-4) : 225 - 232
  • [7] Philadelphia-negative acute lymphoblastic leukemia in a chronic myeloid leukemia patient receiving dasatinib
    Santos, Fabio P. S.
    Rodrigues, Morgani
    Bley Do Nascimento, Claudia Mac-Donald
    Kerbauy, Fabio R.
    Feitosa Ribeiro, Andreza Alice
    Kutner, Jose Mauro
    Hamerschlak, Nelson
    CYTOTHERAPY, 2010, 12 (01) : 113 - 115
  • [8] Molecular cytogenetic characterization of Philadelphia-negative rearrangements in chronic myeloid leukemia patients
    Bennour, Ayda
    Bellaj, Hatem
    Ben Youssef, Yosra
    Elloumi, Moez
    Khelif, Abderrahim
    Saad, Ali
    Sennana, Halima
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2011, 137 (09) : 1329 - 1336
  • [9] Molecular cytogenetic characterization of Philadelphia-negative rearrangements in chronic myeloid leukemia patients
    Ayda Bennour
    Hatem Bellâaj
    Yosra Ben Youssef
    Moez Elloumi
    Abderrahim Khelif
    Ali Saad
    Halima Sennana
    Journal of Cancer Research and Clinical Oncology, 2011, 137 : 1329 - 1336
  • [10] Philadelphia-negative secondary acute myeloid leukaemia during imatinib treatment for chronic phase chronic myeloid leukaemia
    Ross, David M.
    Jackson, Sharon R.
    Browett, Peter J.
    LEUKEMIA & LYMPHOMA, 2007, 48 (06) : 1231 - 1233